Noise & health · 2026
The Impact of Noise Reduction Measures during Noise-Sensitive Periods on Vertigo Symptoms and Vestibular Function in Patients with Ménière's Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Hua, Pan Xu, Lin Dan, Yang XiaoGang, Liu PuZhao
Аннотация
BACKGROUND: Ménière's disease is a chronic vestibular disorder characterised by vertigo, hearing loss and tinnitus, with noise exposure potentially exacerbating symptoms. This study aimed to evaluate the influence of noise reduction measures during noise-sensitive periods on vertigo symptoms and vestibular function in affected patients.
METHODS: This retrospective study included 223 patients diagnosed with Ménière's disease between May 2021 and June 2023. Participants were divided into two groups: the noise reduction measure group (NR group, n = 108) and the non-noise reduction measure group (NNR group, n = 115). Assessments included the Dizziness Handicap Inventory (DHI), Visual Analogue Scale (VAS) for vertigo severity, Pure Tone Audiometry (PTA), video Head Impulse Test, vestibular evoked myogenic potentials, caloric tests, Tinnitus Handicap Inventory (THI), Hospital Anxiety and Depression Scale (HADS) and the 36-Item Short Form Health Survey (SF-36). All measures were obtained at baseline and 3 months after the treatment initiation. Statistical comparisons between groups were performed using independent samples t-tests and chi-square tests, as appropriate.
RESULTS: At the 3-month follow-up, the NR group demonstrated significantly greater improvements than the NNR group in THI (P = 0.011), DHI (P = 0.014), VAS (P < 0.001), PTA thresholds (P = 0.007), vestibular function parameters (all P < 0.05), HADS for anxiety (P = 0.020), HADS for depression (P = 0.014) and multiple SF-36 domains (P < 0.05). The basic vertigo control rate was also higher in the NR group than in the NNR group (P = 0.003).
CONCLUSION: Implementing noise reduction measures during noise-sensitive periods significantly improved vertigo symptoms, reduced tinnitus handicap and enhanced hearing function in patients with Ménière's disease, suggesting that this approach may be a valuable adjunctive approach to standard medical treatment.
METHODS: This retrospective study included 223 patients diagnosed with Ménière's disease between May 2021 and June 2023. Participants were divided into two groups: the noise reduction measure group (NR group, n = 108) and the non-noise reduction measure group (NNR group, n = 115). Assessments included the Dizziness Handicap Inventory (DHI), Visual Analogue Scale (VAS) for vertigo severity, Pure Tone Audiometry (PTA), video Head Impulse Test, vestibular evoked myogenic potentials, caloric tests, Tinnitus Handicap Inventory (THI), Hospital Anxiety and Depression Scale (HADS) and the 36-Item Short Form Health Survey (SF-36). All measures were obtained at baseline and 3 months after the treatment initiation. Statistical comparisons between groups were performed using independent samples t-tests and chi-square tests, as appropriate.
RESULTS: At the 3-month follow-up, the NR group demonstrated significantly greater improvements than the NNR group in THI (P = 0.011), DHI (P = 0.014), VAS (P < 0.001), PTA thresholds (P = 0.007), vestibular function parameters (all P < 0.05), HADS for anxiety (P = 0.020), HADS for depression (P = 0.014) and multiple SF-36 domains (P < 0.05). The basic vertigo control rate was also higher in the NR group than in the NNR group (P = 0.003).
CONCLUSION: Implementing noise reduction measures during noise-sensitive periods significantly improved vertigo symptoms, reduced tinnitus handicap and enhanced hearing function in patients with Ménière's disease, suggesting that this approach may be a valuable adjunctive approach to standard medical treatment.